Bresta Miranda-Palma is an Endocrinology/Metabolic physician affiliated with University of Miami. OpenAlex indexes 13 publications with 1,182 citations (h-index 7).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1450 NW 10th Ave
Miami, FL 331361011
Telephone
305-243-3636Registry record last updated 24 Sept 2014.
Industry payments
3 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- SANOFI-AVENTIS U.S. LLCProgram year20221 payment
- Lilly USA, LLCProgram year20221 payment
- Medtronic, Inc.Program year20211 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
70.3%GLP-1 receptor agonist20.9%Ozempic61%Trulicity19%Mounjaro17%Rybelsus3%Part D<11 patientsInsulin Analog18.2%Tresiba Flextouch U-10021%Lantus Solostar19%Humalog Kwikpen U-10015%Novolog Flexpen12%Basaglar Kwikpen U-1006%Novolog6%Fiasp Flextouch4%Insulin Lispro Kwikpen U-1004%Tresiba Flextouch U-2004%Humalog3%Lyumjev Kwikpen U-1003%Levemir Flexpen3%Part D<11 patients+ 7 more classes in this area
Cardiovascular
14.2%Statin6%Atorvastatin Calcium63%Rosuvastatin Calcium37%Part D≥43 patientsCholesterol absorption inhibitor1.9%Ezetimibe100%Part D≥21 patients+ 7 more classes in this area
Hormonal (systemic)
13.2%l-Thyroxine12.6%Levothyroxine Sodium79%Synthroid21%Part D≥85 patientsThyroid Hormone Synthesis Inhibitor0.7%Methimazole100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- SAT661 Bypass-oma Or Medication-oma: A Clinical Dilemma About Hypoglycemia
Journal of the Endocrine Society
2023 - Efficacy and Safety of Insulin Degludec in a Flexible Dosing Regimen vs Insulin Glargine in Patients With Type 1 Diabetes (BEGIN: Flex T1): A 26-Week Randomized, Treat-to-Target Trial With a 26-Week Extension
The Journal of Clinical Endocrinology & Metabolism
2013
Similar KOLs
Other experts from the same institution or the same specialty.
Robert Myerburg, MD
University of Miami
Thomas Hooton, MD
University of Miami
Harry Flynn, MD
University of Miami
Alan Wein, MD
University of Miami
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”